Kendle Announces Third Quarter 20...(nties include but are not limited to (a)...),Health

Date:11/4/2009

nties include, but are not limited to, (a) competitive factors in the industry, (b) drug-development activity and outsourcing trends in the biopharmaceutical industry, (c) the Company's ability to manage growth, including integration of acquired businesses and implementation of information technology solutions, (d) the Company's dependence on the skills, experience and efforts of its employees and management team in the geographic regions and therapeutic areas in which the Company operates and the risks associated with hiring, managing and retaining members of this team (e) the fixed-price nature of contracts and cost overruns, (f) the loss, cancellation or delay of contracts or amendments thereto, (g) the mix of contracts in the Company's backlog and the sales cycle for these contracts, (h) the Company's ability to service its indebtedness and maintain adequate credit facilities and credit lines, (i) the effects of exchange rate fluctuations, (j) the risks related to the Company's international operations, (k) the amount of goodwill and other intangible assets on the Company's balance sheet and the potential for write-downs of these assets if they become impaired under accounting rules; (l) changes in regulation of the drug-development process, (m) litigation that might arise from patient volunteers in the drug development process, (n) natural disasters, acts of war or other similar events that could have an adverse effect on the Company's operations, and (o) other risks as detailed from time to time in Kendle's Annual Report on Form 10-K as well as periodic reports filed with the SEC. In addition, no assurance can be given that the Company will be able to realize the net service revenues included in backlog. The Company believes that its aggregate backlog is not necessarily a meaningful indicator of future results. All information in this press release is current as of Nov. 4, 2009. The Company undertakes no duty to update any forward-looking statement to conform
'/>"/>

SOURCE Kendle International Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Kendle Announces Details Regarding Second Quarter 2009 Earnings Conference Call and Webcast
2. Kendle to Share Insights at Drug Information Association 45th Annual Meeting
3. Kendle to Present at Upcoming Jefferies and Wachovia Securities Conferences
4. Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast
5. Kendle Expands Asia/Pacific Operations with Opening of Additional Office in India
6. Kendle Revises Full Year 2008 Guidance
7. Kendle to Present at 27th Annual J.P. Morgan Healthcare Conference
8. Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008
9. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
10. Kendle Promotes Simon S. Higginbotham to President; Appoints Alan J. Boyce as Chief Marketing Officer
11. Kendle Delivers Strong Growth in Revenues, New Business Authorizations and Operating Margin for Full-Year 2007; Announces Guidance for 2008